Trial Profile
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs CDX-3379 (Primary) ; Vemurafenib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals
- 03 Apr 2017 Status changed from active, no longer recruiting to completed.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov.